ChinaBio Today -- China life science news last week was dominated by stories of substantial foreign investments in China’s pharmaceutical sector. The Swiss biopharma Novartis (NYSE: NVS) led the way, with nearly $1.4 billion in capital commitments to three separate initiatives in China. The company clearly feels that China represents growth – and Novartis has added significantly to its R&D, technical expertise, vaccine and marketing efforts there.
